PRFX Valuation
PainReform Ltd
$
2.120
- Overview
- Forecast
- Valuation
PRFX Relative Valuation
PRFX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, PRFX is overvalued; if below, it's undervalued.
Historical Valuation
Trailing
Forward
P/E
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
1.75
P/B
Median3y
0.42
Median5y
0.69
-323.35
FCF Yield
Median3y
-324.13
Median5y
-213.92
Competitors Valuation Multiple
The average P/S ratio for PRFX's competitors is 0.33, providing a benchmark for relative valuation. PainReform Ltd Corp (PRFX) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
People Also Watch
VMD
Viemed Healthcare Inc
7.270
USD
-1.76%
VACH
Voyager Acquisition Corp
10.275
USD
-0.15%
FSBW
FS Bancorp Inc
39.640
USD
+0.03%
ACRE
Ares Commercial Real Estate Corp
4.680
USD
+13.59%
RLGT
Radiant Logistics Inc
5.960
USD
+1.36%
MTW
Manitowoc Company Inc
8.560
USD
+2.64%
BLDE
Blade Air Mobility Inc
2.770
USD
+0.36%
NATH
Nathan's Famous Inc
98.820
USD
+0.08%
CRVS
Corvus Pharmaceuticals Inc
3.200
USD
-4.48%
GOCO
Gohealth Inc
8.490
USD
+18.25%
FAQ
Is PainReform Ltd (PRFX) currently overvalued or undervalued?
PainReform Ltd (PRFX) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of 0.00. The fair price of PainReform Ltd (PRFX) is between to according to relative valuation methord.
What is PainReform Ltd (PRFX) fair value?
How does PRFX's valuation metrics compare to the industry average?
What is the current P/B ratio for PainReform Ltd (PRFX) as of May 08 2025?
What is the current FCF Yield for PainReform Ltd (PRFX) as of May 08 2025?
What is the current Forward P/E ratio for PainReform Ltd (PRFX) as of May 08 2025?